Loading...
A140410 logo

Mezzion Pharma Co.,Ltd.KOSDAQ:A140410 Stock Report

Market Cap ₩1.9t
Share Price
n/a
1Y66.8%
7D-8.6%
1D-1.6%
Portfolio Value
​
View

Mezzion Pharma Co.,Ltd.

KOSDAQ:A140410 Stock Report

Market Cap: ₩1.9t

Mezzion PharmaLtd (A140410) Stock Overview

Develops, manufactures, and sells pharmaceutical products in South Korea. More details

A140410 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Earnings have declined by 11.8% per year over past 5 years


A140410 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW463,021 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
463,021 investors already sharing narratives
View all narratives

Mezzion Pharma Co.,Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Mezzion PharmaLtd
Historical stock prices
Current Share Price₩62,800.00
52 Week High₩179,900.00
52 Week Low₩37,350.00
Beta1.13
1 Month Change22.42%
3 Month Change-15.25%
1 Year Change66.80%
3 Year Change45.54%
5 Year Change1.56%
Change since IPO533.28%

Recent News & Updates

Analysis Article • Feb 06

Is Mezzion PharmaLtd (KOSDAQ:140410) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Recent updates

Analysis Article • Feb 06

Is Mezzion PharmaLtd (KOSDAQ:140410) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Oct 18

Is Mezzion PharmaLtd (KOSDAQ:140410) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Mar 13

Here's Why We're Watching Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Nov 02

Here's Why We're Not Too Worried About Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Sep 27

Mezzion Pharma Co.,Ltd.'s (KOSDAQ:140410) Shareholders Might Be Looking For Exit

When close to half the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or "P/S") below...
Analysis Article • Jun 11

Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Mezzion Pharma Co.,Ltd.'s ( KOSDAQ:140410 ) price-to-sales (or "P/S") ratio of 48x may look like a poor investment...
Analysis Article • Mar 04

Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking

The Mezzion Pharma Co.,Ltd. ( KOSDAQ:140410 ) share price has done very well over the last month, posting an excellent...
Analysis Article • Feb 05

We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon

With the business potentially at an important milestone, we thought we'd take a closer look at Mezzion Pharma...
Analysis Article • Dec 14

Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain

For many, the main point of investing in the stock market is to achieve spectacular returns. While the best companies...

Shareholder Returns

A140410KR PharmaceuticalsKR Market
7D-8.6%-1.9%0.4%
1Y66.8%-4.1%106.9%

Return vs Industry: A140410 exceeded the KR Pharmaceuticals industry which returned -4.1% over the past year.

Return vs Market: A140410 underperformed the KR Market which returned 106.9% over the past year.

Price Volatility

Is A140410's price volatile compared to industry and market?
A140410 volatility
A140410 Average Weekly Movement12.1%
Pharmaceuticals Industry Average Movement7.3%
Market Average Movement9.8%
10% most volatile stocks in KR Market17.6%
10% least volatile stocks in KR Market5.1%

Stable Share Price: A140410 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A140410's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200218Dean Parkwww.mezzion.co.kr

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older.

Mezzion Pharma Co.,Ltd. Fundamentals Summary

How do Mezzion PharmaLtd's earnings and revenue compare to its market cap?
A140410 fundamental statistics
Market cap₩1.92t
Earnings (TTM)-₩36.93b
Revenue (TTM)₩7.97b
241.1x
P/S Ratio
-52.0x
P/E Ratio

Is A140410 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A140410 income statement (TTM)
Revenue₩7.97b
Cost of Revenue₩6.59b
Gross Profit₩1.38b
Other Expenses₩38.31b
Earnings-₩36.93b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.21k
Gross Margin17.31%
Net Profit Margin-463.23%
Debt/Equity Ratio68.1%

How did A140410 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/21 17:37
End of Day Share Price 2026/08/21 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mezzion Pharma Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jae Hoon ShinHanwha Investment & Securities Co., Ltd.
Sang-Hun LeeiM Securities
Eun Jung SongNomura Securities Co. Ltd.